

Financial Tear Sheet

Corporate Profile

Altimmune is a clinical stage immunotherapeutic biotechnology company located in Montgomery County, MD with additional operating sites in London, UK and Strasbourg, France. By leveraging the complementary attributes of its two innovative vaccine delivery platforms, RespirVec™ and Densigen™, Altimmune is able to design and develop immunotherapeutic products tailored to address a wide range of disease indications including acute respiratory infections, chronic viral infections and cancer, with the potential for fundamental advantages over competing products.

Corporate Profile


ALT (COMMON STOCK)

\$4.56

Change (%) 0.00 (0.00%)

Volume 10,119

Data as of 05/25/17 12:50 p.m. ET
 Data provided by Nasdaq. Minimum 15 minutes delay
[Refresh quote](#)



Recent Press Releases

May 16, 2017

[ALTIMMUNE PROMOTES DR. SYBIL TASKER TO CHIEF MEDICAL OFFICER](#)

May 10, 2017

[ALTIMMUNE, INC. \(NASDAQ: ALT\) TO RING THE NASDAQ STOCK MARKET OPENING BELL](#)

May 04, 2017

[ALTIMMUNE COMPLETES MERGER WITH PHARMATHENE CREATING IMMUNOTHERAPEUTICS COMPANY TARGETING INFECTIOUS DISEASES](#)

Upcoming Events

There are currently no events scheduled.

Sec Filings

Filing Date	Form	Description	Filing Group
05/16/17	8-K	Report of unscheduled material events or corporate event	Current Reports
05/15/17	8-K	Report of unscheduled material events or corporate event	Current Reports
05/15/17	SC 13G	A statement of beneficial ownership of common stock by certain persons	Other
05/15/17	SC 13D	Filing by person(s) reporting owned shares of common stock in a public company >5%	Other
05/15/17	3	Initial filing by director officer or owner of more than ten percent.	3,4,5
05/15/17	SC 13G	A statement of beneficial ownership of common stock by certain persons	Other

05/10/17	8-K	Report of unscheduled material events or corporate event	Current Reports
05/10/17	S-8	Securities offered to employees pursuant to employee benefit plans	Registration Statements
05/08/17	4	Statement of changes in beneficial ownership of securities	3,4,5
05/08/17	4	Statement of changes in beneficial ownership of securities	3,4,5

Primary IR Contact

Matthew Duffy

Phone: (212) 915-0685

E-mail: matthew@lifesciadvisors.com